SuperworthAllarity Therapeutics ALLR
- Market cap
- $13.8M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | $0 | $0 | n/a | n/a | $25K | $0 | |
| R&D | $1.9M−35% | $2.6M+179% | $2.2M+52% | $1.1M−4% | $1M−48% | $1.8M−30% | $1.4M−35% | $2.3M+119% | $1.2M+18% | $1.7M−9% | $1.3M−8% | $1.3M−42% |
| SG&A | $2.5M+59% | $2.3M+1% | $2.1M−8% | $2.3M−24% | $1.6M−36% | $5.5M+143% | $1.6M−21% | $1.8M−22% | $1.3M−17% | $1.6M−71% | $1.4M−13% | $1.3M−27% |
| −$4.4M−3% | −$4.9M−28% | −$4.2M+16% | −$3.4M−19% | −$12.3M+178% | −$7.3M+50% | −$3M−28% | −$4.1M+23% | −$2.5M−80% | −$2.9M−60% | −$2.7M−12% | −$2.7M−35% | |
| Interest expense | $34K−3% | $230K | $102K+11% | $426K+200% | $50K+47% | $75K−67% | $57K−44% | $12K−97% | $57K+14% | $59K−21% | $229K+302% | $719K+5892% |
| Pre-tax income | −$4.4M−12% | −$1.6M−48% | −$3.8M+15% | −$1.6M−32% | −$12M+169% | −$7.5M+355% | −$2.7M−29% | −$2.3M+42% | −$2.8M−77% | −$3.4M−55% | n/a | n/a |
| $0 | $83K | −$4K | $0 | −$377K | $0 | $0 | $0 | $0 | $0 | n/a | n/a | |
| Net income | −$4.4M−12% | −$1.7M−39% | −$3.8M+15% | −$1.6M−32% | −$11.6M+161% | −$7.5M+333% | −$2.7M−29% | −$2.3M+42% | −$2.8M−76% | −$3.4M−55% | −$2.8M+1% | −$3.4M+47% |
| −$26918.35−95% | −$198.82 | −$7968600.06+4079% | −$2005.38−87% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| 4.1K+34497% | 8.7K+69085% | 5.8K+33094% | 499.3K+80342% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
EPS, diluted: 16 periods, Q3 FY20 to Q2 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY20 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q1 FY21: share-days: the 6-month average less the second quarter's. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Allarity Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ALLRAllarity Therapeutics | $13.8M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Allarity Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .